FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to novel conjugates of a cell-binding agent with a cytotoxic agent in which a cell-binding agent (CBA) is covalently bound to a cytotoxic agent through the engineered Cys, such as the engineered Cys in the heavy chain CH3 domain, at the position corresponding to position 442 (or C442) according to the EU/OU numbering system in the CBA antibody. Present invention also discloses methods of producing conjugates of the invention. Additionally disclosed are a pharmaceutical composition and methods, suitable for inhibiting abnormal cell growth or treating proliferative disorder in a mammal using conjugates of the invention.
EFFECT: disclosed are conjugates of constructed antibodies with cysteine substitutes.
33 cl, 8 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | 2016 |
|
RU2739612C2 |
| MAITANZINOID DERIVATIVES WITH SELF-SPLITTING PEPTIDE LINKERS AND THEIR CONJUGATES | 2018 |
|
RU2765098C2 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE | 2017 |
|
RU2777357C2 |
| LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| CNP PRODRUGS | 2016 |
|
RU2824988C1 |
| COMPOSITIONS AND METHODS RELATING TO DRUG CONJUGATES WITH ANTI-CD19 ANTIBODIES | 2019 |
|
RU2806333C2 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
